Avacta, Daewoong partner on COVID-19 therapy

By The Science Advisory Board staff writers

July 29, 2020 -- Avacta has expanded its collaboration with Daewoong Pharmaceutical to develop stem cell treatments using Avacta's neutralizing Affimer therapy for COVID-19 patients.

AffyXell Therapeutics, the next-generation cell and gene therapy joint venture between Avacta and Daewoong, will develop a novel class of mesenchymal stem cell treatments that are engineered to also produce Affimer therapies in patients at a selected site of action.

Now, the collaboration will also include the development of therapies that repair lung damage caused by COVID-19 while also producing neutralizing Affimer molecules that prevent disease progression.

Avacta's Affimer reagent may neutralize SARS-CoV-2
Avacta Group, the developer of Affimer biotherapeutics and reagents, announced that several Affimer reagents block the interaction between SARS-CoV-2's...

Copyright © 2020 scienceboard.net

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
2020 ACCP Annual Meeting
September 20-22
Bethesda, Maryland United States
Bioprocess International West
September 21-24
Eastern Standard Time Zone (EST) United States
BioProcess International
September 21-24
Eastern Standard Time Zone (EST), Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter